TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00903305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT00698581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
Study: NCT02628795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRT + FM
Description: Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Post-surgical usual care activities including any prescribed physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Post-surgical usual care activities including any prescribed physical therapy
Study: NCT05046041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone + Misoprostol
Description: A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
Study: NCT00031889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane+bicalutamide
Description: Exemestane as in arm I and oral bicalutamide once daily
Study: NCT03745144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
Study: NCT01002833

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to Plasmodium falciparum infected mosquitoes
Description: Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
Study: NCT02229461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: ASA 81 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: ASA 81 mg qd
Study: NCT01002833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exposure to Plasmodium falciparum infected mosquitoes
Description: Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exposure to Plasmodium falciparum infected mosquitoes
Description: Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
Study: NCT02229461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: ASA 81 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: ASA 81 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: ASA 81 mg qd
Study: NCT00896337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epic™ Nitinol Stent System
Description: The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-platelet therapy
Description: Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-coagulation therapy
Description: Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
Study: NCT00691717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: Single administration by anterior juxtascleral depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/mL
Description: Single administration by anterior juxtascleral depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 75 mg/mL
Description: Single administration by anterior juxtascleral depot

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Single administration by anterior juxtascleral depot
Study: NCT02972190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral decompression with TLIF
Description: Bilateral decompression of neural elements combined with TLIF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminectomy with PLIF
Description: Decompression of neural elements using laminectomy combined with PLIF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedicle screw and interbody cage
Description: Pedicle screw and interbody cage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screw and interbody cage
Description: Pedicle screw and interbody cage
Study: NCT02677350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
Description: Peri-fistula injections
Study: NCT00997867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip
Description: Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
Study: NCT00110409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Education in Adults
Description: The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Emergency Room Asthma Education
Description: Participants will receive standard emergency room education about asthma.
Study: NCT03441464

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
Study: NCT03387358

Intervention type: DEVICE
Intervention: Nasal bridle securement device for small bore feeding tubes
Description: A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
Study: NCT03123991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP-A adapted as a preventive intervention
Description: The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Same than experimental group (EG), after EG finishes
Description: The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
Study: NCT02412332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow harvesting
Description: Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow harvesting
Description: Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
Study: NCT00211887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1-a
Description: The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1-a
Description: The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: an inactive substance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT00687531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
Study: NCT00679874

Intervention type: OTHER
Intervention: Cardio-vascular MRI
Description: Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
Study: NCT02089126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin/Glimepiride combination
Study: NCT02022436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contrast Ultrasound
Description: Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contrast Ultrasound
Description: Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
Study: NCT02144116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance-movement therapy
Description: The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
Study: NCT00302458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate
Description: Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate
Description: Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate
Description: Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Methylphenidate
Description: Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Methylphenidate
Description: Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
Study: NCT03334812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA043
Description: LNA043 Single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA043
Description: LNA043 Single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo to LNA043
Description: placebo to LNA043 single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo to LNA043
Description: placebo to LNA043 single dose
Study: NCT00302458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Methylphenidate
Description: Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered during the first part of the day, and again during the second part of the day.
Study: NCT02881645

Intervention type: BEHAVIORAL
Intervention: Best practices
Description: Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
Study: NCT02770586

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breast PET
Description: imaging of the breast using the Breast PET system
Study: NCT03134755

Intervention type: DRUG
Intervention: Inhaled corticosteroid (mometasone)
Description: The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
Study: NCT01064492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
Study: NCT04461782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: Oral food supplement
Study: NCT02863133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Embolic
Description: The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
Study: NCT04177940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMAB Discontinuation and Switching
Description: Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMAB Discontinuation and Switching
Description: Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose
Study: NCT00689611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion HCl ER
Description: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01351155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin protective dressing device
Description: Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin protective dressing device
Description: Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
Study: NCT02625597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotton Pellet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene Tape

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Foam
Study: NCT01351155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin protective dressing device
Description: Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
Study: NCT01004861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered once or twice daily, continuous dosing
Study: NCT03214042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-rod dynamic stabilization system
Description: Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
Study: NCT05420649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-intubated Laryngomicrosurgery
Description: Non-intubated LMS was performed with assistance of Optiflow (HFNO).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-intubated Laryngomicrosurgery
Description: Non-intubated LMS was performed with assistance of Optiflow (HFNO).
Study: NCT03431649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium
Description: 1 mcg /kgbw daily, divided in three dosages orally for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: 0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
Study: NCT01893775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu-Mik- Beta-1
Description: Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
Study: NCT03508232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline Hyclate
Description: Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.